ERBB2 and breast cancer: Over-expression of HER2 due to gene amplification and/or transcriptional dysregulation is observed in about 20% of breast cancers, a smaller proportion of gastric/gastro-oesophageal junction cancers and, less commonly, in other solid tumour types.